2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.46 (Poster) Real-World Rebiopsy and Biomarker Retesting Rates Among Patients With Non–Small Cell Lung Cancer Across Patient Demographics in the United States

PP01.46 (Poster) Real-World Rebiopsy and Biomarker Retesting Rates Among Patients With Non–Small Cell Lung Cancer Across Patient Demographics in the United States

Back to course

Pdf Summary

This study aimed to assess biomarker testing patterns and rebiopsy rates among patients with non-small cell lung cancer (NSCLC) in real-world settings in the United States. The analysis included 4,528 patients with nonsquamous advanced or metastatic NSCLC who received systemic therapy.<br /><br />The results showed that there were differences in rebiopsy rates among different patient subgroups. Patients with wild-type EGFR status, patients who did not receive targeted therapy in the first-line, Black patients, and male patients had lower rates of rebiopsy at the second-line (2L). Male patients also had lower rates of retesting at 2L compared to female patients.<br /><br />Additionally, patients with EGFR wild-type status had lower rates of rebiopsy and retesting at 2L and 3L compared to patients with a known mutation. There were also correlations between patient subgroups and the time to first biomarker test. Black patients had a lower likelihood of 2L rebiopsy compared to White patients, and patients with EGFR wild-type status had a lower likelihood of rebiopsy at 2L and 3L compared to patients with a known mutation.<br /><br />Furthermore, there were regional and age differences in the time to first biomarker test. Patients in regions outside of the Northeast and patients aged 65 years had lower rates of 2L time to first biomarker test.<br /><br />Overall, this study highlights the need for standardization of biomarker testing in later lines of therapy for optimal and equitable treatment decision-making for patients with NSCLC. The findings also demonstrate the presence of genetic, racial, and gender differences in rebiopsy and retesting rates among patients with NSCLC.

Asset Subtitle

Qingquing Xu

Keywords

biomarker testing patterns

rebiopsy rates

NSCLC

real-world settings

systemic therapy

wild-type EGFR status

second-line rebiopsy

retesting rates

time to first biomarker test

equitable treatment decision-making